Business Standard
Sunday, Nov 22, 2009
 
drived banner
drived banner
  Advanced Search
Feedback | RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Smart Portfolios II
  Search:

Aurobindo Pharma gets USFDA approval
BS Reporter / Mumbai November 6, 2009, 11:46 IST

Hyderabad-based, Aurobindo Pharma has received the approval for its chewable and dispersible Lamotrigine tablets from the US Food & Drug Administration (USFDA).

BSE | NSE
Price  
 
 
Related Stories
News Now
-SEZs post Rs 89,000-cr exports in Apr-Sept
-Aurobindo back in black with Rs 103 cr profit
-Genes in a twist
-Aurobindo gets nod to market 2 more products in S Africa
-Experts' panel approves Bt brinjal, final okay now with Jairam
-Commercial use of Bt brinjal soon

With this latest approval, the pharma major has a total of 107 approvals from USFDA in its kitty.

Lamotrigine tablets 5mg and 25mg is generic equivalent to Lamictal CD tablets 5 mg and 25 mg of GlaxoSmithKline, the compay said in a statement today. It falls under the central nervous system (CNS) segment and is indicated as adjunctive therapy for partial seizures and generalised seizures of Lennox-Gastaut syndrome in patients aged 2 years and older.

On the Bombay Stock Exchange, the company's stocks were trading at Rs 828, up 2.44 per cent at IST 1140.

Arrow Other Stories     
- Sensex makes remarkable recovery, regains 17K
- S C Kalia takes over as Union Bank ED
- PNB may acquire majority stake in Kazakh bank
- Maoist hindering land acquisition for Tata steel project: Raman
- Koda says he will report to ED only after Jharkhand polls
More  
  Read Business news in 
  Get financial advisory and solutions for your projects
  Holidays starting at a delightful EMI of Rs 3481
  Switch on and say hello to Monday morning !
  Your dream home can now be a reality.
  Visit Fortis for a preventive health check-up & get a 20% discount.
  Follow the ups and downs of your investments. Try our new Portfolio Tracker
  Kolkata Dock \ Freight contract for the British Gurkhas Nepal
  Find how Midsize Businesses use ERP to gain competitive advantage
  Trading in Forex is now as easy as 1-2-3
  Discover an economical and cost effective way to market your products and services
  Giftwithlove.com: Same day delivery of Flowers and Cakes to India
  Download the E-book on the Future of Business Intelligence
  Learn Best Practices for improving customer satisfaction
  Know your customers better... download the free e-book on CRM
Share this Story  
 
 
   Discussion Board / User Comments    
Display Name  Email-Id  
Post your comment
Most Popular
Read
E-Mailed
Commented
   
- Kurbaan could be Karan Johar's first flop
- A golden lining seen in silver prices
- Ambani Jr, Brad Pitt join hands for sci-fi film
- HAL to invest Rs 25,000 cr in next 10 years
- We are not trying for a monopoly: HAL chairman
 
 More  
BS Poll
Cast Your Vote
 
   
 
Should India's defence sector be thrown open to foreign investments?
  Yes  No
Submit

  Hot Searches  
 
Amitabh Bachchan | N Chandrasekaran | Swine Flu | Mukesh Ambani | Anil Ambani | TCS | Infosys |  Air India |  Duronto |  Pranab Mukherjee | Sonia Gandhi | Congress | Rahul Gandhi |  Bigg Boss |  New Pension Scheme |  Service tax |  Excise duty |  Sebi | Tech Mahindra |  Ramalinga Raju |  Satyam |  Reliance  |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  |  B-School | DLF  Sensex |  Tax calculator | Home Loan  | Bollywood | Personal Finance |  inflation | oil prices |  World Bank | Reliance Infratel |  HDFC |  Barack Obama  
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Site Map | Contact Us | Feedback